NHS England is planning a phased rollout of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), following promising results in clinical trials. The drug has been recommended for patients with obesity at a cost of $159.6 per month for the highest dose. Initially, the rollout plans to reach up to 240,000 people and will trial various cost-effective delivery models, prioritising patients with a BMI above 40 and three or more weight-related conditions.
Federal firings and office closures create concerns for miners
Sweeping layoffs and federal office closures in the US are raising concerns about miner safety and health. Notably, 873 staff cuts are expected from the
